Advertisement

Related Videos

Opportunities to Optimize Cancer Policies Panel Discussion

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Welcome and Introduction to Vi3C

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Advertisement

Advertisement




Apr
28
Today In Oncology
RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer
Early-Onset Lung Cancer May Be Connected to Pesticide Contaminants
ACP Issues Controversial New Breast Cancer Screening Guidelines
Educational Disparities in Young-Onset Colorectal Cancer Mortality
Breast Cancer Clonal Hematopoiesis and Risk of Trastuzumab-Related Cardiotoxicity
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo